

July 22-24, 2019 | Boston, MA
www.microbiome-oncology.com

MICROBIOME MOVEMENT ONCOLOGY RESPONSE

Harness the Microbiome to Optimize Cancer Therapeutic Strategies for Improved Safety & Efficacy Outcomes

Expert Speakers Including:



Jennifer McQuade, MD
Assistant Professor
MD Anderson Cancer Center



Jonathan Peled, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center



Imke Mulder
Director of Research
4D Pharma



Xue Liang
Senior Scientist,
Microbiome/Molecular
Discovery
Merck Exploratory Science Center



Bruce Roberts
Chief Scientific Officer
Vedanta Biosciences



Diwakar Davar, MD
Assistant Professor of
Medicine
University of Pittsburgh

Proud To Partner With:



The Only Industry-Focused Forum Dedicated to Harnessing the Microbiome to Optimize Cancer Therapeutic Strategies for Improved Patient Outcomes


III Increased knowledge of the mechanisms of action underlying the hallmarks of cancer is driving the evolution of cancer therapeutics. More recently, however, a wealth of scientific evidence has demonstrated the impact of the gut microbiome in modulating response and resistance to existing cancer treatments. Additionally, findings have revealed causal and consequential roles of the microbiome in cancer pathogenesis and progression.

The inaugural **Microbiome Movement – Oncology Response Summit** has been established to improve your understanding on how to translate microbiome-oncology research from discovery settings and retrospective clinical investigations into routine oncology practice. This first-of-its-kind event is your opportunity to learn from the expertise of key opinion leaders from pre-clinical, translational and clinical scientists from large pharma, biotech and academia presenting the latest case studies and in-depth discussion on key topics:

- Discover the mechanistic pathways underpinning the causality of the microbiome in cancer and consequential effects of cancer therapeutics on microbial dysbiosis
- Understand how -omics data are being integrated to inform cancer clinical decision making


- Investigate translational applications of the microbiome in cancer 1) as an LBP monotherapy or adjuvant to enhance therapeutic efficacy 2) to overcome toxicity outcomes and 3) as a validated biomarker to predict patient response
- Explore the role of nutrition in cancer treatment and prevention
- Harness clinical experience to establish gold standards for cancer clinical trials incorporating the microbiome as a measurable endpoint
- Uncover how to integrate the microbiome into existing oncology medical practice and drug development infrastructures

There is no question that applying the microbiome in cancer is the next frontier to enhance already existing oncology pipelines. Join us to discover, translate and accelerate microbiome research into optimized cancer therapeutic strategies that improve patient safety and efficacy outcomes. **III**



Trish Kruk
 Program Director
Microbiome Movement

Five Reasons to Attend



Discover cutting-edge research presented by **the Harvard School of Public Health & Fox Chase Cancer Center** in pursuit of causality between microbiome-immune pathways and cancer




Explore novel approaches to defining pre-clinical models that facilitate investigation of *in vivo* interactions between the microbiome and cancer therapeutics with the **Merck Exploratory Science Center**



Assess improvements in patient safety & efficacy outcomes through combination therapeutic approaches harnessing LBPs and microbiome-based biomarkers with **Seres Therapeutics & Memorial Sloan Kettering Cancer Center**



Access clinical case studies from **4D Pharma & University of Pittsburgh** to understand how to design clinical trials that demonstrate the added value of investigating the microbiome in cancer



Understand the wider considerations needed for integrating microbiome R&D into routine oncology practice with **Gusto Global & John Hopkins Hospital**

YOUR EXPERT SPEAKERS



Alex Stevenson
Chief Scientific
Officer
4D Pharma



Imke Mulder
Director of Research
4D Pharma



Maya Kahan-Hanum
CRC Project Leader
BiomX



Christophe Bonny
Chief Scientific
Officer
Enterome Biosciences



Romain Daillère
Head of Preclinical
Research &
Co-Founder
EverImmune



James Burgess
VP Innovation
Finch Therapeutics



Sergei Grivennikov
Assistant Professor
Fox Chase Cancer Center



Daniel van der Lelie
Chief Scientific
Officer
Gusto Global



Wendy Garrett
Professor of
Immunology &
Infectious Diseases
Harvard T.H. Chan School of Public Health



Fyza Shaikh, MD
Postdoctoral Fellow
John Hopkins Hospital



Mingyang Song, MD
Assistant Professor
Massachusetts General Hospital and Harvard Medical School



Jonathan Peled, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center



Xue Liang
Senior Scientist,
Microbiome/
Molecular Discovery
Merck Exploratory Science Center



Jennifer McQuade, MD
Assistant Professor
MD Anderson Cancer Center



Trevor Lawley
Chief Scientific
Officer & Co-
Founder
Microbiotica



Lata Jayaraman
Head of Tumor
Immunotherapy
Seres Therapeutics



Gregory Poore
MD/PhD Candidate
UCSD Centre for Microbiome Innovation



Sandrine Miller-Montgomery
Executive Director,
Center for Microbiome
Innovation -
Professor of Practice,
Bioengineering
UCSD Centre for Microbiome Innovation



Diwakar Davar, MD
Assistant Professor of
Medicine
University of Pittsburgh



Bruce Roberts
Chief Scientific
Officer
Vedanta Biosciences

!!! The value of participating in this meeting is in informing the field about the potential of targeting the microbiome to improve outcomes in cancer patients receiving immunotherapy **!!!**
Diwakar Davar, University of Pittsburgh, Confirmed Speaker

CONFERENCE DAY ONE

TUESDAY, JULY 23

8.00 Registration & Morning Coffee
8.50 Chairperson's Opening Remarks

The Next Frontier in Cancer Innovation - the Human Microbiome

Session Purpose:

As our understanding of the human microbiome matures, there has been an injection of scientific interest and investment into the microbiome-oncology intersection. The cancer community is realizing the next wave of innovation through microbiome-based approaches that improve patient stratification and response to already existing cancer therapies. This theme will highlight the new opportunity set into motion by the collision of microbiome and cancer research.

Lata Jayaraman
Head of Tumor
Immunotherapy
Seres Therapeutics

9.00 Leveraging Gut Microbiota Networks for Impacting Tumor Immunotherapy

- Discovering the concept of “reverse translation” as a strategy for microbiome drug discovery - identification of a microbiome signature and its association with treatment and response
- Using mouse tumor models to validate clinical observations and to optimize microbiome therapies
- Seeing the value of partnering with investigators in premier academic institutions and industry to rapidly bring microbiome therapies to patients

Microbial Dysbiosis in Cancer – Cause or Consequence?

Session Purpose:

Early research has suggested that the microbiome is a contributing causal factor of carcinogenesis but it is unclear to what extent this is the case. It is also unclear whether the tumor microenvironment has a mechanistic role in microbial dysbiosis. This theme will explore evidence for both the causal and consequential interactions between the tumorigenic environment, the immune system and the microbiome.

Jonathan Peled, MD
Medical Oncologist
**Memorial Sloan
Kettering Cancer
Center**

9.30 Exploring the Role of the Intestinal Microbiome in Allogeneic Hematopoietic Cell Transplantation

- Demonstrating that patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) incur rapid changes in their intestinal microbiota
- Demonstrating that these changes in the intestinal microbiota are associated with clinically relevant outcomes in patients undergoing allo-HCT including overall survival and lethal graft-versus-host disease

Wendy Garrett
Professor of
Immunology &
Infectious Diseases
**Harvard T.H. Chan
School of Public
Health**

10.00 Examining the Microbes & Immune Cells Instrumental in Potentiating Carcinogenesis



10.30 Speed Networking & Morning Refreshments

Sergei Grivennikov
Assistant Professor
**Fox Chase Cancer
Center**

11.30 Revealing How Microbiota Controls Inflammation & Cytokines to Promote Colon Cancer

- Exploring how tumor adhesive microbiota stimulate intra-tumoral immune cells
- Demonstrating that the cytokines produced by immune cells in microbiota-dependent manner regulate immunity and tumor promotion
- Highlighting how the effects of microbiota-driven cytokines within the tumor microenvironment may be cell type specific

Fyza Shaikh, MD Postdoctoral Fellow John Hopkins Hospital	12.00 Enhancing Anti-Tumor Immunity via Targeted Alteration of the Microbiome • Developing a clinical program to study microbiome and checkpoint inhibitor success • Discussing how to get the clinical networking in place in order to collect and analyze stool sample data • Complementary approaches in preclinical models to address microbiome and anti-tumor immunity
---	---

Integrating –Omics Data to Understand Causality of the Microbiome in Cancer

Session Purpose:

Light years of progress have been made in terms of genomic characterization of microbes. However, there remains a gap in understanding how to analyze metagenomic, proteomic and pharmacomicrobiomic data and integrate it with clinical data. The purpose of this session will be to explore how we can maximize the knowledge gained from –omics data and how to use it to inform clinical decision making in the cancer setting.

Gregory Poore MD/PhD Candidate UCSD Centre for Microbiome Innovation	12.30 Revolutionizing Dogmas Through Oncobiome Science • Overviewing recent progress in understanding the gut microbiome and its relationship with cancer therapy • Highlighting the recent discovery and utilization of the commensal (tissue) microbiome's impact on cancer's initiation, progression, and treatment resistance • Discussing the implications of these findings and technological approaches to developing microbially-sensitive cancer diagnostics, prognostics, and therapeutics
--	---

13.00 Lunch & Networking

Understanding the Role of Nutrition in Cancer Treatment & Prevention

Session Purpose:

Whilst the majority of applications of the microbiome in cancer focus on its curative potential, there is a significant amount of research being done into understanding its preventative role and as a nutritional intervention. This theme will showcase the early clinical and pre-clinical work investigating how the microbiome can be used to treat and prevent cancer.

Jennifer McQuade, MD Assistant Professor MD Anderson Cancer Center	14.00 Exploring Diet, the Microbiome & Response to Immunotherapy • Understanding how a high fiber diet is associated with improved response to immunotherapy • Revealing how the gut microbiome can be modulated through dietary interventions • Demonstrating that probiotics are associated with a lower diversity of the gut microbiome
--	---

Mingyang Song, MD Assistant Professor Massachusetts General Hospital and Harvard Medical School	14.30 Exploring Marine Omega-3 Fatty Acid & Colorectal Cancer Prevention & Treatment: The Role of the Gut Microbiome & Tumor Immunity • Protecting against colorectal cancer through higher intake of marine omega-3 fatty acid • Supporting the benefit of marine omega-3 fatty acid for colorectal cancer survival through epidemiologic evidence • Addressing how these benefits may be mediated by modulation of the gut microbiome and tumor immunity
---	---

Identifying Microbial Profiles as Prognostic Biomarkers & Defining Considerations for Live Biotherapeutic Product Development

Session Purpose:

One application of the microbiome in cancer is through the use of microbiome-based live biotherapeutic products (LBPs). The development of LBPs goes hand in hand with the identification of defined microbial signatures as prognostic biomarkers that can be used to identify (non)-responders to cancer therapies. This theme will explore how the microbiome is being used as a biomarker of response to cancer treatment and how the microbiome itself, can be harnessed to treat cancer.

Trevor Lawley Chief Scientific Officer & Co-Founder Microbiotica	15.00 Applying Microbiotica's Platform to Modulate Cancer Immunotherapy Response & Identify Bacterial Biomarkers & Medicines
	15.30 Afternoon Refreshments & Networking
Bruce Roberts Chief Scientific Officer Vedanta Biosciences	16.00 Enhancing Anti-Tumor Immunity via Targeted Alteration of the Microbiome Leveraging translational medicine data and pre-clinical findings to generate rationally-designed consortia that augment anti-tumour immunity
Alex Stevenson Chief Scientific Officer 4D Pharma	16.30 Into the Clinic: Challenges & Opportunities - Manufacturing: DIY or outsourcing – the pros and cons - Clinical trial design: the successful protocol – adding in the factors to demonstrate effect of LBPs - Microbiome analysis: so much data, so little time - managing the analysis
James Burgess VP Innovation Finch Therapeutics	17.00 Focusing on Human-First Discovery: A Model for Translatable Drug Discovery in Microbial Therapeutics - Developing both full-spectrum microbiota and rationally-selected microbiota products permits the development of therapies that are optimized for a given disease biology - Understanding how clinical interventional data are a powerful tool for deconvoluting metagenomic datasets and identifying clinically relevant microbial strains - Selecting strains for LBP consortia from clinically-demonstrated strains greatly mitigates translational risk and accelerates development timelines
	17.30 Chairperson's Closing Remarks
	17.40 Close of Conference Day One

!!! This is a timely event in light of recent research published on the microbiome and cancer immunotherapy. It is critical to bring the leaders in this field, both from academia and industry, to discuss the advancement as well as challenges that the community is facing. I look forward to a productive discussion forum **!!!**

Xue Liang, Merck Exploratory Science Center, Confirmed Speaker

CONFERENCE DAY TWO

WEDNESDAY, JULY 24

	7.30 Registration & Morning Coffee
	8.20 Chairperson's Opening Remarks
Harnessing the Microbiome as an Adjuvant that Improves Patient Response to Other Cancer Therapies	
Session Purpose: Whilst immune checkpoint inhibitors (ICIs) gave the role of the microbiome in cancer therapy response the spotlight, investigating the role of the microbiome in this context surpasses the checkpoint era. This theme explores monotherapy and combination therapeutic strategies that involve priming the microbiome to enhance or modulate patient response to other cancer therapies.	
Christophe Bonny Chief Scientific Officer Enterome Biosciences	8.30 Outlining Enterome's Onco-Mimics Program: Microbiome-Derived Immunotherapy for Treatment of Cancers - Clarifying how targeting novel antigens called onco-mimics can induce cytotoxic T-cell response against tumors in combination with checkpoint inhibitors - Understanding how EO2401 can be used in patients with Glioblastoma Multiforme (GBM)
Imke Mulder Director of Research 4D Pharma	9.00 Developing Live Biotherapeutics to Target Immuno-Oncology - Discussing how LBPs offer a novel approach to immuno-oncology in monotherapy and combination settings - Addressing how MRx0518 inhibits tumour growth in multiple preclinical models, affects tumour immune populations and has a strong immunostimulatory profile - Pinpointing mode of action: TLR5-mediated immune activation via bacterial flagellin
Diwakar Davar, MD Assistant Professor of Medicine University of Pittsburgh	9.30 Discovering the Role of Microbiome Modulation in Treating PD-1 Non-Responders in Melanoma - Learning how intestinal dysbiosis is linked with adverse outcomes to PD-1 blockade in melanoma and other cancers - Outlining the clinical trials attempting to target intestinal dysbiosis are ongoing in melanoma and other cancers - Evaluating whole fecal microbiome transplantation for proof of concept in PD-1 refractory disease
Xue Liang Senior Scientist, Microbiome/ Molecular Discovery Merck Exploratory Science Center	10.00 Revealing the Effects of the Microbiome on Response to Cancer Immunotherapy - Recognizing that pre-clinical models are critical components towards mechanistic understanding of the role of microbiome - Building internal clinical-relevant preclinical models to seek for the underlying biology - Applying the systems biology approach to investigate novel approaches to augment host responses to cancer immunotherapy
	10.30 Morning Refreshments & Networking
Romain Daillère Head of Preclinical Research & Co-Founder EverImmune	11.30 Improving Cancer Treatment Through Oncobax-Based Therapeutics - Discovering how intestinal commensals dictate our systemic and anticancer immunity - Harnessing the microbiome for the discovery of diagnosis and understanding why therapeutic tools in cancer are key for modulating the clinical outcome of anticancer regimens - Developing Oncobax-based therapeutics to improve the efficacy of anticancer treatments

Putting the Spotlight on Phage Therapy Approaches in Cancer

Session Purpose:

An increasing body of research has highlighted the renaissance of phage therapy as a therapeutic class with huge clinical potential in cancer patients. The purpose of this theme is to showcase the mechanistic pathways of phage therapy and its application as a cancer therapeutic.

Maya Kahan-Hanum CRC Project Leader BiomX	12.00 Utilizing Customized Phages to Treat Bacteria-Associated Colorectal Cancer • Showcasing a growing body of evidence that the presence of <i>F. nucleatum</i> bacteria within colorectal tumours promotes tumour growth and resistance to cancer therapeutics • Developing a novel phage therapy of engineered phage for targeted eradication of <i>F. nucleatum</i> • Providing better treatment care for CRC patients through conventional therapeutics in combination with customized phage therapies
---	---

12.30 Lunch & Networking
Integrating Microbiome-Based Approaches into Routine Oncology Practice
Session Purpose:

It is vital to address where we stand with current microbiome-oncology research and innovation efforts. The purpose of this theme will be to discuss how this field will evolve in the near future as microbiome considerations are integrated into cancer drug development strategies and routine oncology medical practice

Fyza Shaikh, MD Postdoctoral Fellow John Hopkins Hospital Daniel van der Lelie Chief Scientific Officer Gusto Global Lata Jayaraman Head of Tumor Immunotherapy Seres Therapeutics	13.30 Panel Discussion: Where do we Stand with Current Innovation & Future Integration of Microbiome-Based Approaches into Routine Oncology Practice? • What are physicians concerned about when considering microbiome-based approaches in cancer care, and how can these concerns be addressed? • What is the biggest bottleneck in achieving success with microbiome-based approaches in the oncology space? • Having discussed the various applications of the microbiome in cancer over the past two days (1 - LBP as an adjuvant for improved safety, 2 - for improved efficacy, 3 - as a patient stratification factor), which application will be most impactful in the short and long term? • If we weren't cost-limited, how could we accelerate microbiome-based LBPs to the cancer drug market? • What would we like to know about large pharma's assessment of the potential of the microbiome in cancer?
--	---

Breakout Roundtables
Session Purpose:

A holistic understanding of infrastructure requirements is needed to realize the full potential of the various applications of the microbiome in cancer care. This session will facilitate open discussion amongst participants in an informal setting. After splitting into groups, participants will have the opportunity to discuss one of the following questions:

1. 14.10 Microbiome & Immuno-Oncology

As the immuno-oncology market moves from discovery to product approval, how should microbiome innovation be incorporated at a strategic level into anticancer drug development?

2. 14.10 Prognostics & Diagnostics

Does the potential for discovering, validating and developing cancer microbiome prognostic and diagnostic devices bring us closer to the era of precision medicine?

3. 14.10 Microbiome Sample Collection in Clinical Trials

What considerations are needed for cancer clinical trials that integrate microbiome sample collection in both prospective and retrospective settings?

15.00 Chairperson's Closing Remarks
15.10 End of the 1st Microbiome Movement – Oncology Response Summit

PRE-CONFERENCE WORKSHOP

MONDAY, JULY 22

Reading Signals from the Noise: Working Smartly with –Omics to Inform Clinical Decision Making

13:00 – 16:00

With advanced sequencing and analysis technologies, a vast amount of data is being generated to understand the interactions between microbiota and cancer immunity. This interactive workshop will give you the opportunity to understand:

- Sampling logistics for sequencing purposes – what samples are needed? How can we store samples? How to handle samples and what is the best method of transporting them?

- What layers of data can be yielded by different types of sequencing approaches in the context of cancer patient biopsies?
- How to integrate these data with bioinformatics, other –omics approaches and clinical data to make better clinical decisions

Workshop Leaders



Gregory Poore
 MD/PhD Candidate
UCSD Centre for Microbiome Innovation

Gregory Poore is an MD/PhD candidate funded by the NIH's Medical Scientist Training Program grant who is working in Rob Knight's lab to bring together two fields that do not frequently communicate: oncology and microbiology. His passion for the subject originates from losing his grandmother, who over the course of 4 weeks in 2013, went from a sudden diagnosis of pancreatic cancer to passing despite targeted chemotherapy.

This catalyzed his research in cancer genomics at Duke-NUS (Singapore), where his work was co-authored in multiple publications across Nature Genetics, Genome Medicine, and Leukemia. Upon his return to Duke University in the USA, his research interests broadened to include infectious disease genomics, machine learning techniques, and multi-omic integration. When the first major cancer microbiome paper was published in September, 2017, showing chemo-degrading bacteria living in more than half of pancreatic cancer patients, the message hit close to home and his subsequent research focus was decided. His strategies of study to characterize, predict, and treat the cancer microbiome extend from bioinformatics and machine learning to histopathology and technology development.



Sandrine Miller-Montgomery
 Executive Director, Center for Microbiome Innovation - Professor of Practice, Bioengineering
UCSD Centre for Microbiome Innovation

Dr. Sandrine Miller-Montgomery is co-leading UC San Diego Centre for Microbiome Innovation, as executive director with Pr. Rob Knight. In this position, she is leading a team focused on fostering and expanding industry and academic collaborations, with the mission of accelerating Microbiome discovery and creating innovative technologies that will support this emerging but exploding field in the consumer world as well as enabling major clinical breakthroughs. She is building the success of the center based on scientific excellence from the leadership team as well as her own business expertise after years in industry.

Indeed, previously, she was the leading MO BIO Laboratories, a QIAGEN Company, focusing on nucleic acid purification solutions for challenging samples, such as ones found in Microbiome

studies. Sandrine was previously their Director of Sales and Marketing, where she led a team, which consistently grew the business at a rate far superior to the market rate, ultimately resulting into its acquisition by QIAGEN.

She has held Global Marketing Manager positions at large companies such as Abbott Laboratories or Illumina (following the acquisition of Helixis). Before Helixis, Sandrine had work for many years at Invitrogen, now part of Thermo Fisher, starting as a bench scientist, then R&D Manager, followed by being one of their first Program Managers and ultimately migrating to the business side as Product Manager for both qPCR reagents and Reverse Transcriptase portfolio. She came into the USA from France in 2000 to join Genetix, in their R&D department focusing on the identification of Obesity and Diabetes cure candidates.

Sandrine received both her Pharm.D and her Ph.D. in Life Science from the University of Bordeaux (France), with emphasis on molecular biology, biology of aging and thrombosis and hemostasis.

PARTNER WITH US

As our understanding of the human microbiome begins to mature, oncology-microbiome research is seeing an injection of scientific interest, collaborations and investment. Researchers and therapeutic developers are now on the look-out for the most innovative service providers with experience in microbial genome sequencing and analysis, *in vitro* and *in vivo* model provision, study design and contract manufacturing.

The **Microbiome Movement – Oncology Response Summit** is the perfect opportunity to demonstrate your technology, experience and thought leadership to meet the increasing demands of this emerging field.

Why Partner?



Benefit from Market Intelligence

Microbiome-oncology research opens the opportunity to develop a range of diagnostic, prognostic or therapeutic products with applications in a wide range of cancers with well-established immune-related causal pathways. Hear how and where biotech companies are looking for services and solutions to facilitate their R&D platforms and match your solutions accordingly.



Raise Brand Awareness

Benefit from pre and post conference exposure to our microbiome-oncology KOL community and increase market share through unique branding formats. Also, differentiate your discovery, pre-clinical and translational services from other solution providers.



Position Yourself as an Industry Expert

With the emergence of biotech companies focused on microbiome-based products for oncology research and patient care, followed by interest shown from large pharma and investors, this meeting is a dedicated platform to put your independent expertise in front of the key decision makers in the field.



Meet and Network with Industry Pioneers


With a room full of oncologists and microbiome-based product developers looking to see how they can effectively translate the microbiome into cancer therapeutic strategies for improved patient response, meet prospective clients during speed networking breaks, 1-2-1 meetings and more informal networking receptions.




Generate Commercial Collaborations

Make sure your hottest prospects are in the room and part of the discussion by having a wish-list of your choice contacted in advance of the event.

Seniority:



Company by Type:



* Statistics based on the *Microbiome Movement – Drug Development* Boston & Europe Summits 2017/8

GET INVOLVED



Adam Haras-Gummer

Partnerships Director

Tel: +44 (0) 203 1418 727

Email: partner@microbiome-movement.com

PROUD TO PARTNER WITH



Exhibition Partner

With more than 20 years' experience, Wacker Biotech is "THE MICROBIAL Contract Development and Manufacturing Organization" (CDMO) – the partner of choice for the manufacturing of therapeutic proteins, vaccines and live microbial products. Wacker Biotech's sites in Jena, Halle (Germany) and

Amsterdam (Netherlands) provide a complete range of services for the development and GMP-compliant manufacture of biopharmaceuticals. The service portfolio covers process & analytical development and the GMP manufacturing of biologics for clinical trials and commercial supply.

www.wacker.com/biologics



Exhibition Partner

Accelerate and transform your research across the entire project lifecycle and capitalize on the diverse opportunities of the microbiome. Diversigen provides comprehensive microbiome, metagenomics, host genetic services, customized study design,

and complex data analysis – all focused on solutions to improve human and animal health, environmental conditions, and agriculture production worldwide.

www.diversigen.com



HEALTH THROUGH MICROBIOTA

Exhibition Partner

Biose Industrie is a Contract Development and Manufacturing Organization (CDMO), specialised in Live Biotherapeutic Products. Founded in 1951 by pharmacists and microbiologists, Biose Industrie has been manufacturing drug substance and drug

products based on microorganisms for 60 years. Company, with 10 000m² of GMP facility, offers product development at laboratory and pilot scale specialised in microbiology for aerobic and anaerobic strains and is Drug GMP certified for the manufacturing of API, clinical batches and commercial products.

www.biose.com/en/cdmo

 The agenda for *Microbiome Movement – Oncology Response Summit 2019* encompasses the key questions needed to move the microbiome cancer field forward – including the microbiome as a prognostic biomarker, mechanisms, and microbiome modulation 

Jennifer McQuade, MD Anderson Cancer Center, Confirmed Speaker

JOIN THE MICROBIOME MOVEMENT



January 2019: Paris, FR
microbiome-europe.com

 The event organization and content was flawless. This is a premier event for the microbiome biotech and pharma industry. 
Jim Brown, Senior Fellow Director in Computational Biology, GSK



February 2019: Raleigh, NC
microbiome-agbiotech.com

 Possibly the best conference in the agricultural microbiome space - a great mix of basic scientific research and product development from universities, multinationals and start-up companies. Congratulations! 
Marcus Meadows-Smith, CEO, BioConsortia



May 2019: Boston, MA
microbiome-infant-health.com

 This is great opportunity to learn and connect with thought leaders who are on the forefront in the emerging areas of maternal and infant microbiome health 
Noah Voreades, GenBiome Consulting, Confirmed Speaker



June 2019: Boston, MA
microbiome-summit.com

 This meeting is possibly the best in the microbiome field for a biotech company, for networking and hearing the latest developments. 
Mike Romanos, CEO, Microbiotica



September 2019: San Diego, CA
microbiome-dermatology.com

 This meeting was the perfect balance between basic/ applied science and academic/commercial interests. 
Greg Hillebrand, Senior Principal Research Scientist, Amway



October 2019: St. Louis, MO
microbiome-animal.com

 I really enjoyed meeting critical innovators within Animal Health and learn more about how technologies within this space and developing and the key problems being addressed. 
Megan Lyman, Director, IP, Regulatory & Product Development, AgTech Accelerator



November 2019: Boston, MA
microbiome-nutrition.com

 If you want to learn about the latest developments and mix with the movers and shakers in the industry, you HAVE to be there. 
Alan Murray, CEO, NextFoods Inc



December 2019: Boston, MA
gutbrain-axis.com

 It is one of the best meeting I've been to! Great job! 
Yanjiao Zhou, Research Scientist, The Jackson Laboratory



THE PROMISE OF THE MICROBIOME MOVEMENT

Dear Microbiome Enthusiast,

 As the knowledge of the microbiome continues to deepen, fundamental understanding of mechanism of action and demonstrating causality continue to improve. As such, the *Microbiome Movement* has become more committed than ever to work alongside innovative researchers and industry leaders to build events that focus on applied science and translate cutting-edge microbiome R&D into safe, effective and commercially successful products across a number of industry-specific verticals.

Positioned at the heart of pharmaceutical, agricultural, nutritional and animal health R&D, the *Microbiome Movement* continues to help accelerate the discovery, development and delivery of breakthrough solutions to global challenges to benefit human health. For each specific industry where the microbiome will have a real impact, we're building an exclusive community for you to maximize the opportunity.

We build every event from six key pillars to make sure everything you read, watch and experience will truly help you gain better insight and ultimately help drive the microbiome community together.

This is our promise to you. 



Passion

We love this space and believe in its long term impact, and we know you do too



Integrity

Showcasing only the most cutting-edge and scientifically validated research, data and best practice into our programs



Quality

Deep market research allows us to cut through the noise and share relevant insights that are important to you



Specificity

Each event agenda is independently designed and curated with a clear narrative to suit your industries' needs



Originality

Adapting with a fast growing community to accelerate your research across healthcare, agriculture and beyond



Trail-Blazing

Staying one step ahead of the latest opportunities and trends, to keep you informed and help make better commercial decisions

**We really hope you can join us on this journey and be a part of the microbiome revolution.
Long Live The Microbiome!**



Trish Kruk
Program Director
Microbiome Movement

3 EASY WAYS TO BOOK

-  www.microbiome-oncology.com
-  Tel: +1 617 455 4188
-  Email: register@hansonwade.com

TOP 3 REASONS TO ATTEND:

- 1 Explore novel applications of the microbiome that optimize safety and efficacy outcomes for cancer patients
- 2 Learn from the expertise of key opinion leaders and discover pioneering data-driven case studies that showcase discovery, pre-clinical and clinical data on the role of the microbiome in cancer
- 3 Uncover and forge the collaborations you need to develop effective and commercially successful cancer therapeutic strategies informed by knowledge of the human microbiome

SECURE YOUR PLACE

Industry Pricing	Register & Pay By Friday, May 24	Standard Pricing
Conference + Workshop	\$2498 (save \$500)	\$2898 (save \$100)
Conference Only	\$1999 (save \$400)	\$2399
Workshop Only	\$599	
Academic & Start-Up Pricing	Register & Pay By Friday, May 24	Standard Pricing
Conference + Workshop	\$1598 (save \$500)	\$1998 (save \$100)
Conference Only	\$1299 (save \$400)	\$1699
Workshop Only	\$399	

Team Discounts

Maximize value for money using special team discounts:

- **10% discount – 2 delegates**
- **15% discount – 3 delegates**
- **20% discount – 4+ delegates**

Please note that discounts are only valid when two or more delegates from one company book and pay at the same time. Group discounts cannot be used in conjunction with other discount codes or offers, other than the early booking rates.

For more information on group discount eligibility, rates and booking, please contact: register@hansonwade.com

***Start-up and academic rates are subject to organizer approval. Please visit event website for further details, or email: register@hansonwade.com to apply**



VENUE

The Revere Boston Common Hotel
 200 Stuart Street, Boston
 Massachusetts 02116

For further information or assistance, please visit www.reverehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH